Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small cell lung cancer. Its programs also include vaccines that are in pre-clinical stage, which includes EVX-B1 for the prevention of S. aureus-induced skin and soft tissue infections in patients undergoing elective abdominal hernia surgery; EVX-B2 to target diseases caused by N. gonorrhoeae; EVX-B3 for eliciting strong humoral antibody and cellular immune response to the bacterial pathogen; and EVX-V1, a viral vaccine product candidate for targeting Cytomegalovirus. The company was formerly known as Evaxion Biotech A/S and changed its name to Evaxion A/S in May 2025. Evaxion A/S was incorporated in 2008 and is based in Horsholm, Denmark.
Metrics to compare | EVAX | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipEVAXPeersSector | |
---|---|---|---|---|
P/E Ratio | −1.1x | −1.2x | −0.5x | |
PEG Ratio | −0.01 | −0.06 | 0.00 | |
Price / Book | 1.4x | 1.3x | 2.6x | |
Price / LTM Sales | 4.5x | 6.9x | 3.0x | |
Upside (Analyst Target) | - | 162.9% | 52.6% | |
Fair Value Upside | Unlock | 43.0% | 8.7% | Unlock |